Drug Profile
ES 4000
Alternative Names: ES-4000Latest Information Update: 17 Dec 2021
Price :
$50
*
At a glance
- Originator ESCEND PHARMACEUTICALS
- Class Antineoplastics; Small molecules
- Mechanism of Action Beta catenin inhibitors; CCND1 protein degraders; Cyclin D inhibitors; Proto oncogene protein c-myc inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Chronic myeloid leukaemia; Pancreatic cancer; Triple negative breast cancer
Most Recent Events
- 17 Dec 2021 Preclinical development is ongoing in Pancreatic cancer in USA (PO) (Escend Pharmaceuticals pipeline; December 2021)
- 17 Dec 2021 Preclinical development is ongoing in Acute myeloid leukaemia in USA (PO) (Escend Pharmaceuticals pipeline; December 2021)
- 17 Dec 2021 Preclinical development is ongoing in Chronic myeloid leukaemia in USA (PO) (Escend Pharmaceuticals pipeline; December 2021)